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Stroke rehabilitation has been accepted as an integral part of the continuum of care in comprehensive stroke 
management program in the developed world. It has been demonstrated that outcomes are better in patients who are 
treated in stroke units offering comprehensive acute care and coordinated post stroke rehabilitation.1 Comprehensive 
stroke rehabilitation is associated with improved functional outcome, reduced rate of complications, smaller length of 
stay and better community re-integration. 2,3 Guidelines are an important set of recommendations which provide a 
unified frame work for the physicians and health care professionals regarding best practices in the management of a 
disease and medical problem. Many countries have issued stroke management and rehabilitation guidelines in the last 
two decades.4 All major stroke management guidelines recommend stroke rehabilitation as part of the overall stroke 
management program.5 Adherence to stroke guidelines is associated with improved stroke outcomes including 
functional recovery,6 better survival rates,7 reduced healthcare costs8 and patient satisfaction.9 Pakistan society of 
neurology issued the ischemic stroke management guidelines in 2010, but stroke rehabilitation is not addressed 
adequately. The available guidelines on stroke rehabilitation are all from the developed countries with better health care 
system and availability of integrated multi-disciplinary stroke rehabilitation teams. There is a paucity of quality research 
on stroke rehabilitation in local context and “rehabilitation is still confused with physiotherapy rather than the concept 
of a multi-disciplinary team approach” There is a dire need to develop new guidelines or adapt the existing stroke 
rehabilitation guidelines according to our local context, resources and expertise. It has been recognized that updating 
guidelines is a difficult task, particularly in a low resourced developing country.10 Therefore it is necessary that these 
guidelines are devised by inviting all stake holders and making a consensus panel, but at the same time it is necessary 
to avoid what is described as: ‘small meetings of experts [making policies] behind closed doors’.11 I propose the 
following framework for development/ update of stroke rehabilitation guidelines in context of Pakistan and other similar 
low resourced countries.
• Pakistan society of Physical Medicine and Rehabilitation should collaborate with the Pakistan Society of 
Neurorehabilitation and Pakistan society of Neurology for development of Stroke rehabilitation guidelines for Pakistan.
The core panel should consist of physiatrists ( Rehabilitation medicine physicians) and neurologists with interest in 
neurorehabilitation).
• Allied health care professionals like physical therapists, occupational therapist, and speech and language 
pathologists should also be part of the guidelines development panel.
• Experts with qualification in their particular field with at least five years of post-qualification clinical experience and 
an established track record of research and publications should be invited for the panel.
• There should be an open call for the guidelines panel and the prospective candidates can be shortlisted and finalized 
by a committee of experts.
• Instead of developing the guidelines from the scratch it is recommended that the existing guidelines be consulted 
and adapted to our local needs. The panel should consider the availability of resources, healthcare system, local 
constraints and awareness regarding stoke rehabilitation while formulating these guidelines.
• Alternatives and low resourced stroke rehabilitation interventions must be identified in these guidelines e.g. 
Botulinum toxin for post stroke spasticity is recommended but is costly and not widely available throughout Pakistan. 
Phenol blocks for spasticity management are cost effective and an effective alternative in resistant spasticity.
• Guidelines should be multi-disciplinary encompassing all aspects of a comprehensive stroke rehabilitation program 
instead of focusing only on the medicines or physiotherapy.
• Once the guidelines are formulated they should be submitted for external peer review by involving external experts 
and officially mandating an external review committee.
• “Task forces should be provided with tools to grade locally acquired evidence. Otherwise they may overstate the 
contribution of western textbooks.” 10 
• Once the guidelines have been updated/ finalized after the external peer review they should be submitted for formal 
publication in leading biomedical journals in the country. A copy of the guidelines should be sent to all practicing 
physiatrists and neurologists in the country with a request to adhere to the guideline while managing stroke patients.
I believe that in this era of evidence based medicine and personalized medicine, no stroke patient in Pakistan should 
be discharged to home without a long term rehabilitation plan. These guidelines might provide the framework towards 
better integration of acute stroke care with the long term rehabilitation plan which would benefit the patient, his/her 
family  and the society in general.
Those interested in contributing towards stroke rehabilitation guidelines development should contact Dr Farooq Rathore 
at farooqrathore@gmail.com
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INTRODUCTION
Homocysteine has gained significant attention in the 
last decade for its atherogenic properties. Various 
studies have shown that moderate elevation of the 
plasma level of this metabolite has been associated with 
increased risk for cardiovascular and cerebrovascular 
disease (1,2,3). Besides causing atherosclerosis, raised 
homocysteine levels also increase the risk of vascular 
dementia and Alzheimer’s disease (3) Homocysteine 
levels may be moderately elevated secondary to 
deficiency of enzyme co-factors involved in 
homocysteine metabolism (i.e. Vitamin B12, B6
and folate) and genetic polymorphism in 
methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) (3,4). In addition, plasma 
levels of homocysteine are influenced by other factors. 
Increased levels are associated with high blood 
pressure, elevated cholesterol levels,(5) smoking, 
increasing age and gender (more prevalent in males) (3,6) 
Vascular injury induced by moderately elevated levels of 
homocysteine is characterised by intimal thickening,
disruption of elastic lamina, smooth muscle 
proliferation, platelet accumulation, and formation of 
platelet plugs (7,8). Studies are now being done to 
determine whether vitamin therapy reduces the risk of 
ischemic stroke and stroke-related disability (9). HOPE-2 
(Heart Outcomes Prevention Evaluator 2) study shows 
that although homocysteine-lowering therapies did not 
improve the outcome of cardiovascular death, MI and 
stroke, but the risk of stroke was reduced by around 
25%, after a fair duration of treatment of three years in 
persons younger than 70 years with untreated 
hyperlipidemia, not receiving antiplatelets and with 
hyperhomocysteinemia or folate and vitamin B12 
deficiency(10,11).  Although the VISP (Vitamin Intervention 
for Stroke Prevention) trial showed that high-dose 
multivitamin therapy did not help in preventing recurrent 
stroke, the control agent used in the trial contained 
small doses of vitamin B6, B12, and folic acid, and the 
reduction of homocysteine level was less than that 
expected in the study. 12 Besides these, 
four meta-analyses reporting on the benefit of folic acid 
or vitamin B supplementation have been published in
2010(13,14,15,16).
OBJECTIVE
To observe the frequency of increased homocysteine levels 
in patients with ischemic stroke, presenting to our private 
tertiary care centre, regardless of their age, gender, race
and social status; and its association with other risk factors.
RESULTS
Out of the 75 enrolled patients, 33(44%) had 
moderately elevated homocysteine level, 10(13.3%) 
had severely elevated level of more than 30Đmol/l 
(Table 1). The mean homocysteine level was 19.52 
(SD: +/- 11.47)Đmol/l, with the minimum being 7.02Đ
mol/l and the maximum 50Đmol/l. The mean folate 
level was 7.15 (SD: +/- 4.51)ng/ml, with a minimum of 
1.12ng/ml and a maximum of 21.50ng/ml. The mean 
vitamin B12 level was 432.55 (SD: +/- 293.53) pg/ml; 
minimum, 150pg/ml and maximum, 1000pg/ml
Table 1
Table 2 
Thirty-four of our patients were less than 60 years of 
age and the mean homocysteine level in this group was 
21.26 (SD: +/-13.55) Đmol/l. In the 41 patients who 
were more than and equal to 60 years, the mean 
homocysteine level was 18.07(SD: +/- 9.32) Đmol/l. 
The difference in the two groups was statistically not 
significant (p= 0.250). The mean homocysteine level 
of the male patients (41 in number) was 22.44(SD: 
+/-13.38)Đmol/ l and that of the female patients was 
15.98(SD: +/- 7.37), with a significant statistical 
difference between the two (p=0.010). There were 15 
patients who had folic acid deficiency and the mean 
homocysteine level in this group was 27.49(SD: +/- 
13.83)Đmol/l, compared to the 60 patients with normal 
folic acid levels, whose mean homocysteine level was 
17.52(SD: +/-9.97)Đmol/l. The difference among the 
two groups was statistically significant with a p-value of 
0.017. 15 of the patients who were vitamin 
B12-deficient had a mean homocysteine level of 
28.41(SD: +/- 14.80)Đmol/l, and those with normal 
values had a mean level of 17.29(SD: +/- 9.37)Đmol/l. 
Statistical difference was significant between the two 
groups (p=0.013). Out of the 75 patients, 70 were 
hypertensive, with a mean homocysteine level of 
19.40(SD: +/-11.52) Đmol/l. The mean homocysteine 
value of the 5 non-hypertensive patients was 
21.13(SD: +/-11.87) Đmol/l, with no significant 
statistical difference between the two groups 
(p=0.747). Increased cholesterol level was present in 
20 patients and their mean homocysteine value was 
16.99(SD: +/-11.99) Đmol/l. In the group of patients 
with normal cholesterol level (55 patients), the mean 
homocysteine level was 20.44(SD: +/-11.24) Đmol/l; 
the statistical difference being not significant between 
the two groups (p=0.252). Similarly, no significant 
statistical difference was present between the smokers 
and non-smokers (p=0.565). There were 14 smokers, 
with a mean homocysteine value of 17.91(SD: +/- 
13.60) Đmol/l, and 61 non-smokers, with mean 
homocysteine level of 19.88(SD: +/-11.02) Đmol/l.
DISCUSSION
The study showed a strong association between 
hyperhomocysteinemia and stroke, with 44%of the 
patients having moderately elevated levels and 13.3% 
having severely elevated levels of more than 30Đmol/l, 
making a total of 53.3% of patients. Various studies 
have shown that homocysteine levels increase with age 
(3,6), although our study speculates that there is no 
association between hyperhomocysteinemia and 
increasing age, as the difference in mean homocysteine 
levels was statistically not significant. We also looked 
for association between increased homocysteine levels 
and gender. As described in different studies previously 
(3,6), our study also showed a significant difference in 
mean homocysteine levels between males and 
females. Males had higher propensity to hyperhomocy- 
steinemia than females. Deficiency of enzyme 
co-factors involved in homocysteine metabolism (i.e. 
Vitamin B12, B6 and folate) and genetic polymorphism 
in methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) are alleged to cause 
hyperhomocysteinemia (3,4). In our patients, the patients 
who were deficient in vitamin B12 and folic acid had a 
greater predilection to hyperhomocysteinemia than 
those having normal vitamin B12 and folic acid values, 
with a significant statistical difference in the mean 
homocysteine value between the two groups. Similarly, 
other variables that are individually associated with both 
hyperhomocysteinemia and ischemic stroke, were 
evaluated, that is hypertension, increased cholesterol 
levels (5) and smoking (3,6). The group of patients that 
were non-hypertensive also had an elevated mean 
homocysteine value and the difference in the mean 
level between the hypertensive and non-hypertensive 
group was statistically not significant. In the same way, 
there was no significant statistical difference in the 
mean homocysteine value between the group of 
patients having increased cholesterol levels and that 
with normal cholesterol levels. So, it can be speculated 
that increased cholesterol levels do not directly relate to 
hyperhomocysteinemia. Non-smokers had a higher 
mean homocysteine value, compared to the smokers, 
the difference being statistically non-significant, 
showing that there is no association between this 
variable and hyperhomocysteinemia.
CONCLUSION
It is speculated that hyperhomocysteinemia is an 
imperative risk factor for stroke in our population. 
Although the patients had other risk factors as well that 
individually contribute to stroke but the role of   
homocysteine in vascular diseases should be 
considered. Large studies should be conducted on our 
local population, to determine the absolute risk of 
having high levels of homocysteine on stroke, and trials 
should be conducted to observe the effect of 
homocysteine-lowering therapy on its incidence. Many 
studies have shown that the routine use of such 
therapies does not decrease the risk of stroke,17 but 
there is evidence that homocysteine-lowering therapy 
helps in secondary prevention in individuals with 
ischemic stroke. Since homocysteine-lowering therapy 
does not appear to have any major side effects and is 
rather cost-effective, it should be considered for use in 
these patients (though with caution in patients with 
renal failure or decreased glomerular filtration rate, in 
whom more active forms i.e. methylcobolamin and 
tetrahydrofolate are recommended).17
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Stroke rehabilitation has been accepted as an integral part of the continuum of care in comprehensive stroke 
management program in the developed world. It has been demonstrated that outcomes are better in patients who are 
treated in stroke units offering comprehensive acute care and coordinated post stroke rehabilitation.1 Comprehensive 
stroke rehabilitation is associated with improved functional outcome, reduced rate of complications, smaller length of 
stay and better community re-integration. 2,3 Guidelines are an important set of recommendations which provide a 
unified frame work for the physicians and health care professionals regarding best practices in the management of a 
disease and medical problem. Many countries have issued stroke management and rehabilitation guidelines in the last 
two decades.4 All major stroke management guidelines recommend stroke rehabilitation as part of the overall stroke 
management program.5 Adherence to stroke guidelines is associated with improved stroke outcomes including 
functional recovery,6 better survival rates,7 reduced healthcare costs8 and patient satisfaction.9 Pakistan society of 
neurology issued the ischemic stroke management guidelines in 2010, but stroke rehabilitation is not addressed 
adequately. The available guidelines on stroke rehabilitation are all from the developed countries with better health care 
system and availability of integrated multi-disciplinary stroke rehabilitation teams. There is a paucity of quality research 
on stroke rehabilitation in local context and “rehabilitation is still confused with physiotherapy rather than the concept 
of a multi-disciplinary team approach” There is a dire need to develop new guidelines or adapt the existing stroke 
rehabilitation guidelines according to our local context, resources and expertise. It has been recognized that updating 
guidelines is a difficult task, particularly in a low resourced developing country.10 Therefore it is necessary that these 
guidelines are devised by inviting all stake holders and making a consensus panel, but at the same time it is necessary 
to avoid what is described as: ‘small meetings of experts [making policies] behind closed doors’.11 I propose the 
following framework for development/ update of stroke rehabilitation guidelines in context of Pakistan and other similar 
low resourced countries.
• Pakistan society of Physical Medicine and Rehabilitation should collaborate with the Pakistan Society of 
Neurorehabilitation and Pakistan society of Neurology for development of Stroke rehabilitation guidelines for Pakistan.
The core panel should consist of physiatrists ( Rehabilitation medicine physicians) and neurologists with interest in 
neurorehabilitation).
• Allied health care professionals like physical therapists, occupational therapist, and speech and language 
pathologists should also be part of the guidelines development panel.
• Experts with qualification in their particular field with at least five years of post-qualification clinical experience and 
an established track record of research and publications should be invited for the panel.
• There should be an open call for the guidelines panel and the prospective candidates can be shortlisted and finalized 
by a committee of experts.
• Instead of developing the guidelines from the scratch it is recommended that the existing guidelines be consulted 
and adapted to our local needs. The panel should consider the availability of resources, healthcare system, local 
constraints and awareness regarding stoke rehabilitation while formulating these guidelines.
• Alternatives and low resourced stroke rehabilitation interventions must be identified in these guidelines e.g. 
Botulinum toxin for post stroke spasticity is recommended but is costly and not widely available throughout Pakistan. 
Phenol blocks for spasticity management are cost effective and an effective alternative in resistant spasticity.
• Guidelines should be multi-disciplinary encompassing all aspects of a comprehensive stroke rehabilitation program 
instead of focusing only on the medicines or physiotherapy.
• Once the guidelines are formulated they should be submitted for external peer review by involving external experts 
and officially mandating an external review committee.
• “Task forces should be provided with tools to grade locally acquired evidence. Otherwise they may overstate the 
contribution of western textbooks.” 10 
• Once the guidelines have been updated/ finalized after the external peer review they should be submitted for formal 
publication in leading biomedical journals in the country. A copy of the guidelines should be sent to all practicing 
physiatrists and neurologists in the country with a request to adhere to the guideline while managing stroke patients.
I believe that in this era of evidence based medicine and personalized medicine, no stroke patient in Pakistan should 
be discharged to home without a long term rehabilitation plan. These guidelines might provide the framework towards 
better integration of acute stroke care with the long term rehabilitation plan which would benefit the patient, his/her 
family  and the society in general.
Those interested in contributing towards stroke rehabilitation guidelines development should contact Dr Farooq Rathore 
at farooqrathore@gmail.com
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INTRODUCTION
Homocysteine has gained significant attention in the 
last decade for its atherogenic properties. Various 
studies have shown that moderate elevation of the 
plasma level of this metabolite has been associated with 
increased risk for cardiovascular and cerebrovascular 
disease (1,2,3). Besides causing atherosclerosis, raised 
homocysteine levels also increase the risk of vascular 
dementia and Alzheimer’s disease (3) Homocysteine 
levels may be moderately elevated secondary to 
deficiency of enzyme co-factors involved in 
homocysteine metabolism (i.e. Vitamin B12, B6
and folate) and genetic polymorphism in 
methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) (3,4). In addition, plasma 
levels of homocysteine are influenced by other factors. 
Increased levels are associated with high blood 
pressure, elevated cholesterol levels,(5) smoking, 
increasing age and gender (more prevalent in males) (3,6) 
Vascular injury induced by moderately elevated levels of 
homocysteine is characterised by intimal thickening,
disruption of elastic lamina, smooth muscle 
proliferation, platelet accumulation, and formation of 
platelet plugs (7,8). Studies are now being done to 
determine whether vitamin therapy reduces the risk of 
ischemic stroke and stroke-related disability (9). HOPE-2 
(Heart Outcomes Prevention Evaluator 2) study shows 
that although homocysteine-lowering therapies did not 
improve the outcome of cardiovascular death, MI and 
stroke, but the risk of stroke was reduced by around 
25%, after a fair duration of treatment of three years in 
persons younger than 70 years with untreated 
hyperlipidemia, not receiving antiplatelets and with 
hyperhomocysteinemia or folate and vitamin B12 
deficiency(10,11).  Although the VISP (Vitamin Intervention 
for Stroke Prevention) trial showed that high-dose 
multivitamin therapy did not help in preventing recurrent 
stroke, the control agent used in the trial contained 
small doses of vitamin B6, B12, and folic acid, and the 
reduction of homocysteine level was less than that 
expected in the study. 12 Besides these, 
four meta-analyses reporting on the benefit of folic acid 
or vitamin B supplementation have been published in
2010(13,14,15,16).
OBJECTIVE
To observe the frequency of increased homocysteine levels 
in patients with ischemic stroke, presenting to our private 
tertiary care centre, regardless of their age, gender, race
and social status; and its association with other risk factors.
RESULTS
Out of the 75 enrolled patients, 33(44%) had 
moderately elevated homocysteine level, 10(13.3%) 
had severely elevated level of more than 30Đmol/l 
(Table 1). The mean homocysteine level was 19.52 
(SD: +/- 11.47)Đmol/l, with the minimum being 7.02Đ
mol/l and the maximum 50Đmol/l. The mean folate 
level was 7.15 (SD: +/- 4.51)ng/ml, with a minimum of 
1.12ng/ml and a maximum of 21.50ng/ml. The mean 
vitamin B12 level was 432.55 (SD: +/- 293.53) pg/ml; 
minimum, 150pg/ml and maximum, 1000pg/ml
Table 1
Table 2 
Thirty-four of our patients were less than 60 years of 
age and the mean homocysteine level in this group was 
21.26 (SD: +/-13.55) Đmol/l. In the 41 patients who 
were more than and equal to 60 years, the mean 
homocysteine level was 18.07(SD: +/- 9.32) Đmol/l. 
The difference in the two groups was statistically not 
significant (p= 0.250). The mean homocysteine level 
of the male patients (41 in number) was 22.44(SD: 
+/-13.38)Đmol/ l and that of the female patients was 
15.98(SD: +/- 7.37), with a significant statistical 
difference between the two (p=0.010). There were 15 
patients who had folic acid deficiency and the mean 
homocysteine level in this group was 27.49(SD: +/- 
13.83)Đmol/l, compared to the 60 patients with normal 
folic acid levels, whose mean homocysteine level was 
17.52(SD: +/-9.97)Đmol/l. The difference among the 
two groups was statistically significant with a p-value of 
0.017. 15 of the patients who were vitamin 
B12-deficient had a mean homocysteine level of 
28.41(SD: +/- 14.80)Đmol/l, and those with normal 
values had a mean level of 17.29(SD: +/- 9.37)Đmol/l. 
Statistical difference was significant between the two 
groups (p=0.013). Out of the 75 patients, 70 were 
hypertensive, with a mean homocysteine level of 
19.40(SD: +/-11.52) Đmol/l. The mean homocysteine 
value of the 5 non-hypertensive patients was 
21.13(SD: +/-11.87) Đmol/l, with no significant 
statistical difference between the two groups 
(p=0.747). Increased cholesterol level was present in 
20 patients and their mean homocysteine value was 
16.99(SD: +/-11.99) Đmol/l. In the group of patients 
with normal cholesterol level (55 patients), the mean 
homocysteine level was 20.44(SD: +/-11.24) Đmol/l; 
the statistical difference being not significant between 
the two groups (p=0.252). Similarly, no significant 
statistical difference was present between the smokers 
and non-smokers (p=0.565). There were 14 smokers, 
with a mean homocysteine value of 17.91(SD: +/- 
13.60) Đmol/l, and 61 non-smokers, with mean 
homocysteine level of 19.88(SD: +/-11.02) Đmol/l.
DISCUSSION
The study showed a strong association between 
hyperhomocysteinemia and stroke, with 44%of the 
patients having moderately elevated levels and 13.3% 
having severely elevated levels of more than 30Đmol/l, 
making a total of 53.3% of patients. Various studies 
have shown that homocysteine levels increase with age 
(3,6), although our study speculates that there is no 
association between hyperhomocysteinemia and 
increasing age, as the difference in mean homocysteine 
levels was statistically not significant. We also looked 
for association between increased homocysteine levels 
and gender. As described in different studies previously 
(3,6), our study also showed a significant difference in 
mean homocysteine levels between males and 
females. Males had higher propensity to hyperhomocy- 
steinemia than females. Deficiency of enzyme 
co-factors involved in homocysteine metabolism (i.e. 
Vitamin B12, B6 and folate) and genetic polymorphism 
in methylenetetrahydrofolatereductase (enzyme involved 
in homocysteine metabolism) are alleged to cause 
hyperhomocysteinemia (3,4). In our patients, the patients 
who were deficient in vitamin B12 and folic acid had a 
greater predilection to hyperhomocysteinemia than 
those having normal vitamin B12 and folic acid values, 
with a significant statistical difference in the mean 
homocysteine value between the two groups. Similarly, 
other variables that are individually associated with both 
hyperhomocysteinemia and ischemic stroke, were 
evaluated, that is hypertension, increased cholesterol 
levels (5) and smoking (3,6). The group of patients that 
were non-hypertensive also had an elevated mean 
homocysteine value and the difference in the mean 
level between the hypertensive and non-hypertensive 
group was statistically not significant. In the same way, 
there was no significant statistical difference in the 
mean homocysteine value between the group of 
patients having increased cholesterol levels and that 
with normal cholesterol levels. So, it can be speculated 
that increased cholesterol levels do not directly relate to 
hyperhomocysteinemia. Non-smokers had a higher 
mean homocysteine value, compared to the smokers, 
the difference being statistically non-significant, 
showing that there is no association between this 
variable and hyperhomocysteinemia.
CONCLUSION
It is speculated that hyperhomocysteinemia is an 
imperative risk factor for stroke in our population. 
Although the patients had other risk factors as well that 
individually contribute to stroke but the role of   
homocysteine in vascular diseases should be 
considered. Large studies should be conducted on our 
local population, to determine the absolute risk of 
having high levels of homocysteine on stroke, and trials 
should be conducted to observe the effect of 
homocysteine-lowering therapy on its incidence. Many 
studies have shown that the routine use of such 
therapies does not decrease the risk of stroke,17 but 
there is evidence that homocysteine-lowering therapy 
helps in secondary prevention in individuals with 
ischemic stroke. Since homocysteine-lowering therapy 
does not appear to have any major side effects and is 
rather cost-effective, it should be considered for use in 
these patients (though with caution in patients with 
renal failure or decreased glomerular filtration rate, in 
whom more active forms i.e. methylcobolamin and 
tetrahydrofolate are recommended).17
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